Peripheral Blood Progenitor Cell Transplantation in Multiple Myeloma Following High-Dose Melphalan-Based Therapy

摘要: The objective of our study was to evaluate the efficacy and toxicity a high-dose melphalan-based therapy with or without total body irradiation (TBI) followed by peripheral blood progenitor cell (PBPC) transplantation in patients multiple myeloma. Between June 1992 1996, 104 (71 male, 33 female) median age 51 years (range 30–65 years) underwent at center. PBPC were mobilized using chemotherapy treatment G-CSF. Fifty treated TBI+melphalan 140 mg/m2 while 54 received melphalan 200 mg/m2. Following autografting, time attainment platelets ≥20×109/l neutrophils ≥0.5×109/l 11 14 days, no difference between groups. In TBI group significantly longer periods parenteral nutrition required due occurrence severe mucositis. Two from died transplantation-related complications. treatment, remission state improved 43 out 102 patients. No statistically significant advantage reaching complete partial observed TBI+high-dose compared alone. optimal particular reference inclusion omission TBI, should be prospectively investigated.